Extended Data Fig. 9: Pro-survival effect of systematic therapy of AAV.CPP.16-aPD-L1 in a genetic GBM tumor model. | Nature Biomedical Engineering

Extended Data Fig. 9: Pro-survival effect of systematic therapy of AAV.CPP.16-aPD-L1 in a genetic GBM tumor model.

From: Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood–brain barrier in rodents and primates

Extended Data Fig. 9

a, Experimental timeline. GBM1694 tumor cells with human wild-type EGFR over-expression and Ink4a/Arf-PTEN co-deletion were implanted into BALB/c mice to model GBM. 1 × 1012 vg of AAV.CPP.16-CAG-aPD-L1-HA were administered at day 5 post tumor implantation. b, Kaplan–Meier survival curves showing survival times of AAV.CPP.16-aPD-L1 or PBS control. n = 6 each group, Log-rank test used to define statistical significance.

Source data

Back to article page